Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc.（ACUR）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ACUR · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
0
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Acura Pharmaceuticals, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ACUR 季度内部人买卖趋势
ACUR 内幕交易卖出 · ACUR 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ACUR CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ACUR 高管卖出股份 · ACUR 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jan 2, 2026 | THANGARAJ IMMANUEL Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2026 | SKELLY WILLIAM G Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2026 | ROSS GEORGE K Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2025 | THANGARAJ IMMANUEL Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2025 | SKELLY WILLIAM G Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2025 | ROSS GEORGE K Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2024 | ROSS GEORGE K Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2024 | SKELLY WILLIAM G Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2024 | THANGARAJ IMMANUEL Director | Option | 50,000 | $500 | Form 4 |
| Jan 2, 2024 | WESSON BRUCE F Director | Option | 37,500 | $375 | Form 4 |
| Nov 20, 2023 | Seiser Robert A VP, Treasurer & Controller | Option | 40,000 | $400 | Form 4 |
| Nov 20, 2023 | Jones Robert B President & CEO | Option | 40,000 | $400 | Form 4 |
| Nov 20, 2023 | CLEMENS PETER A Senior VP & CFO | Option | 40,000 | $400 | Form 4 |
| Nov 20, 2023 | Brzeczko Albert W See Remarks | Option | 40,000 | $400 | Form 4 |
| Jan 3, 2023 | Seiser Robert A VP, Treasurer & Controller | Option | 20,000 | — | Form 4 |
| Jan 3, 2023 | Jones Robert B President & CEO | Option | 50,000 | — | Form 4 |
| Jan 3, 2023 | CLEMENS PETER A Senior VP & CFO | Option | 40,000 | — | Form 4 |
| Jan 3, 2023 | Brzeczko Albert W See Remark | Option | 34,000 | — | Form 4 |
| Jan 3, 2023 | ROSS GEORGE K Director | Option | 66,666 | — | Form 4 |
| Jan 3, 2023 | WESSON BRUCE F Director | Option | 66,666 | — | Form 4 |
| Jan 3, 2023 | THANGARAJ IMMANUEL Director | Option | 66,666 | — | Form 4 |
| Jan 3, 2023 | SKELLY WILLIAM G Director | Option | 66,666 | — | Form 4 |
| Aug 3, 2022 | Brzeczko Albert W VP, Pharma Sciences - APT | Option | 43,333 | $433 | Form 4 |
| Aug 3, 2022 | Brzeczko Albert W VP, Pharma Sciences - APT | Option | 43,333 | — | Form 4 |
| Aug 3, 2022 | Jones Robert B President & CEO | Option | 63,666 | — | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ACUR 内幕交易
ACUR 内幕交易
Acura Pharmaceuticals, Inc.（ACUR）内幕交易数据来源于公司内部人（包括THANGARAJ IMMANUEL (Director), SKELLY WILLIAM G (Director), ROSS GEORGE K (Director)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。ACUR内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Acura Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ACUR 内幕交易 · 5个问题Acura Pharmaceuticals, Inc.（ACUR）的内部人包括高管和董事，如THANGARAJ IMMANUEL (Director), SKELLY WILLIAM G (Director), ROSS GEORGE K (Director)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026